FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2920941623> ?p ?o ?g. }

• W2920941623 endingPage "89" @default.
• W2920941623 startingPage "80" @default.
• W2920941623 abstract "Purpose We sought to evaluate longer-term efficacy and safety of intravitreal aflibercept monotherapy (IAI) vs IAI plus rescue photodynamic therapy (rPDT) in patients with polypoidal choroidal vasculopathy (PCV). Design This was a prospective multicenter, double-masked, sham-controlled randomized clinical study across 62 centers. Methods In this phase 3b/4 study, patients with PCV with best-corrected visual acuity of 73–24 Early Treatment Diabetic Retinopathy Study letters (20/40–20/320 Snellen equivalent) received IAI 2 mg every 4 weeks until week 12, when they were randomized 1:1 to receive IAI or IAI plus rPDT if rescue criteria were met. Patients not requiring rescue received IAI every 8 weeks; those requiring rescue received IAI every 4 weeks plus sham/active PDT. At week 52 (the primary endpoint), IAI was noninferior to IAI plus rPDT. After week 52, treatment intervals could be extended beyond 8 weeks at the investigators' discretion. Noninferiority of IAI vs IAI plus rPDT for mean best-corrected visual acuity change from baseline to week 96 was evaluated. Results Over 96 weeks, 54 patients (17.0%) met rescue criteria. At week 96, IAI was noninferior to IAI plus rPDT in terms of Early Treatment Diabetic Retinopathy Study letters gained (+10.7 vs +9.1, P = .48). Proportions of patients with complete polyp regression (33.1% vs 29.1%) or without active polyps (82.1% vs 85.6%) were similar. In year 2, the mean number of injections was 4.6 in both arms. No new safety signals were observed. Conclusion IAI monotherapy was noninferior to IAI with rescue PDT up to 96 weeks, and functional and anatomical improvements achieved at 52 weeks were maintained. Few patients required rescue PDT, which provided no additional visual benefit. We sought to evaluate longer-term efficacy and safety of intravitreal aflibercept monotherapy (IAI) vs IAI plus rescue photodynamic therapy (rPDT) in patients with polypoidal choroidal vasculopathy (PCV). This was a prospective multicenter, double-masked, sham-controlled randomized clinical study across 62 centers. In this phase 3b/4 study, patients with PCV with best-corrected visual acuity of 73–24 Early Treatment Diabetic Retinopathy Study letters (20/40–20/320 Snellen equivalent) received IAI 2 mg every 4 weeks until week 12, when they were randomized 1:1 to receive IAI or IAI plus rPDT if rescue criteria were met. Patients not requiring rescue received IAI every 8 weeks; those requiring rescue received IAI every 4 weeks plus sham/active PDT. At week 52 (the primary endpoint), IAI was noninferior to IAI plus rPDT. After week 52, treatment intervals could be extended beyond 8 weeks at the investigators' discretion. Noninferiority of IAI vs IAI plus rPDT for mean best-corrected visual acuity change from baseline to week 96 was evaluated. Over 96 weeks, 54 patients (17.0%) met rescue criteria. At week 96, IAI was noninferior to IAI plus rPDT in terms of Early Treatment Diabetic Retinopathy Study letters gained (+10.7 vs +9.1, P = .48). Proportions of patients with complete polyp regression (33.1% vs 29.1%) or without active polyps (82.1% vs 85.6%) were similar. In year 2, the mean number of injections was 4.6 in both arms. No new safety signals were observed. IAI monotherapy was noninferior to IAI with rescue PDT up to 96 weeks, and functional and anatomical improvements achieved at 52 weeks were maintained. Few patients required rescue PDT, which provided no additional visual benefit." @default.
• W2920941623 created "2019-03-22" @default.
• W2920941623 creator A5000253151 @default.
• W2920941623 creator A5011236728 @default.
• W2920941623 creator A5018898425 @default.
• W2920941623 creator A5022217015 @default.
• W2920941623 creator A5030829436 @default.
• W2920941623 creator A5059466214 @default.
• W2920941623 creator A5070007977 @default.
• W2920941623 creator A5072258594 @default.
• W2920941623 creator A5072634175 @default.
• W2920941623 creator A5078487748 @default.
• W2920941623 creator A5081069230 @default.
• W2920941623 date "2019-08-01" @default.
• W2920941623 modified "2023-09-30" @default.
• W2920941623 title "Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: Two-Year Results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study" @default.
• W2920941623 cites W1964763543 @default.
• W2920941623 cites W1968189763 @default.
• W2920941623 cites W1976433015 @default.
• W2920941623 cites W2003324689 @default.
• W2920941623 cites W2004117352 @default.
• W2920941623 cites W2013326233 @default.
• W2920941623 cites W2022878833 @default.
• W2920941623 cites W2034867018 @default.
• W2920941623 cites W2055337835 @default.
• W2920941623 cites W2057062801 @default.
• W2920941623 cites W2059736977 @default.
• W2920941623 cites W2066499272 @default.
• W2920941623 cites W2068742492 @default.
• W2920941623 cites W2084151222 @default.
• W2920941623 cites W2124415048 @default.
• W2920941623 cites W2134161293 @default.
• W2920941623 cites W2150416945 @default.
• W2920941623 cites W2162529998 @default.
• W2920941623 cites W2276207462 @default.
• W2920941623 cites W2319705424 @default.
• W2920941623 cites W2321748845 @default.
• W2920941623 cites W2338221729 @default.
• W2920941623 cites W2519471690 @default.
• W2920941623 cites W2533538659 @default.
• W2920941623 cites W2609337735 @default.
• W2920941623 cites W2626334457 @default.
• W2920941623 cites W2737562804 @default.
• W2920941623 cites W2763376487 @default.
• W2920941623 cites W2778969273 @default.
• W2920941623 cites W2783373665 @default.
• W2920941623 cites W2800507258 @default.
• W2920941623 cites W2801493520 @default.
• W2920941623 cites W2827990227 @default.
• W2920941623 cites W4211020962 @default.
• W2920941623 cites W4247214019 @default.
• W2920941623 cites W4249438516 @default.
• W2920941623 cites W4361738959 @default.
• W2920941623 doi "https://doi.org/10.1016/j.ajo.2019.02.027" @default.
• W2920941623 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30849345" @default.
• W2920941623 hasPublicationYear "2019" @default.
• W2920941623 type Work @default.
• W2920941623 sameAs 2920941623 @default.
• W2920941623 citedByCount "67" @default.
• W2920941623 countsByYear W29209416232019 @default.
• W2920941623 countsByYear W29209416232020 @default.
• W2920941623 countsByYear W29209416232021 @default.
• W2920941623 countsByYear W29209416232022 @default.
• W2920941623 countsByYear W29209416232023 @default.
• W2920941623 crossrefType "journal-article" @default.
• W2920941623 hasAuthorship W2920941623A5000253151 @default.
• W2920941623 hasAuthorship W2920941623A5011236728 @default.
• W2920941623 hasAuthorship W2920941623A5018898425 @default.
• W2920941623 hasAuthorship W2920941623A5022217015 @default.
• W2920941623 hasAuthorship W2920941623A5030829436 @default.
• W2920941623 hasAuthorship W2920941623A5059466214 @default.
• W2920941623 hasAuthorship W2920941623A5070007977 @default.
• W2920941623 hasAuthorship W2920941623A5072258594 @default.
• W2920941623 hasAuthorship W2920941623A5072634175 @default.
• W2920941623 hasAuthorship W2920941623A5078487748 @default.
• W2920941623 hasAuthorship W2920941623A5081069230 @default.
• W2920941623 hasConcept C118487528 @default.
• W2920941623 hasConcept C126322002 @default.
• W2920941623 hasConcept C134018914 @default.
• W2920941623 hasConcept C168563851 @default.
• W2920941623 hasConcept C188816634 @default.
• W2920941623 hasConcept C2776694085 @default.
• W2920941623 hasConcept C2777802072 @default.
• W2920941623 hasConcept C2778257484 @default.
• W2920941623 hasConcept C2778749236 @default.
• W2920941623 hasConcept C2779829184 @default.
• W2920941623 hasConcept C555293320 @default.
• W2920941623 hasConcept C71924100 @default.
• W2920941623 hasConceptScore W2920941623C118487528 @default.
• W2920941623 hasConceptScore W2920941623C126322002 @default.
• W2920941623 hasConceptScore W2920941623C134018914 @default.
• W2920941623 hasConceptScore W2920941623C168563851 @default.
• W2920941623 hasConceptScore W2920941623C188816634 @default.
• W2920941623 hasConceptScore W2920941623C2776694085 @default.
• W2920941623 hasConceptScore W2920941623C2777802072 @default.
• W2920941623 hasConceptScore W2920941623C2778257484 @default.
• W2920941623 hasConceptScore W2920941623C2778749236 @default.
• W2920941623 hasConceptScore W2920941623C2779829184 @default.

• next